Hacker News Reader

There are companies pursuing CAR-T for veterinary treatments that are driving the costs down. One example I'm aware of is LEAH Labs (https://leahlabs.com) that is working on using CAR-T to make affordable cancer treatments in dogs.

Full Disclosure: I am an investor in LEAH Labs.

Why is that a better course of action than investing resources in making the existing and effective treatment more affordable?

From what I've heard the bottleneck for CAR-T is the lack of technicians who can do the work and automation it make more effective use of the technicians and their time.

It seems like there is a clear path to decreasing the cost of this.

Why not both? It's not like those are the only two things in the world. Maybe they're both way more useful than a thousand other ways we spend our money.

The problem is Erooms law. Yes we need to invest more, but we also need to figure out why we're getting worse at doing it year over year. My hypothesis, many others, is that the models are flawed. We need better, more fluid models.